SCHEMBL12375436

SCHEMBL12375436

CC1(CS(=O)(=O)c2ccc(Br)cc2)COC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLCG1 P19174 1/20 0.48
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CA2 P00918 3/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 5/20 0.36
GRK2 P25098 2/20 0.36
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
KEAP1 Q14145 1/20 0.35
NFE2L2 Q16236 1/20 0.35
TP53 P04637 1/20 0.35
USP2 O75604 1/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MMP2 P08253 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL155292 0.85 ALDH1A1 (0.47) CYP3A4CYP2C9CYP2C19TDP1CA2
SCHEMBL23329453 0.78 PLCG1 (0.46) PLCG1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL12375435 0.77 CA1 (0.44) CA2CA12CA9CA1
SCHEMBL13219698 0.75 PLCG1 (0.55) PLCG1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL21761061 0.74 SMN1; SMN2 (0.49) KMT2AALDH1A1GAASMN1; SMN2TSHR
SCHEMBL21760976 0.73 PDE3B (0.33)
SCHEMBL15231846 0.72 PLCG1 (0.47) PLCG1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL22557538 0.72 AOC2 (0.47) PLCG1CA2KMT2APOLBALDH1A1
SCHEMBL14710653 0.72 KEAP1 (0.64) PLCG1KMT2APOLBGRK2ALDH1A1
SCHEMBL12409198 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331503-B1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2013-08-21 EP disclosed
US-8334288-B2 4-phenoxymethylpiperidines as modulators of GPR119 activity IRM LLC (BM) 2012-12-18 US disclosed
US-8334288-B2 4-phenoxymethylpiperidines as modulators of GPR119 activity IRM LLC (BM) 2012-12-18 US disclosed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
WO-2010006191-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR4, GPR180 PLCG1 1935/4885CYP1A2 934/4885CYP3A4 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.